Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-202 Ophthalmic Solution Phase I Single and Multiple Dose Study
jRCT2051210197Phase 1Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ROH-202 with Placebo (2 arms). Primary endpoints: Safety and Pharmacokinetics. Started Mar 2022; status: completed.
02
Drugs
ROH-202
Beyond the preview
Go deeper on jRCT2051210197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210197.